RU2754446C2 - Композиции, относящиеся к мутантному токсину CLOSTRIDIUM DIFFICILE, и способы их применения - Google Patents

Композиции, относящиеся к мутантному токсину CLOSTRIDIUM DIFFICILE, и способы их применения Download PDF

Info

Publication number
RU2754446C2
RU2754446C2 RU2015154443A RU2015154443A RU2754446C2 RU 2754446 C2 RU2754446 C2 RU 2754446C2 RU 2015154443 A RU2015154443 A RU 2015154443A RU 2015154443 A RU2015154443 A RU 2015154443A RU 2754446 C2 RU2754446 C2 RU 2754446C2
Authority
RU
Russia
Prior art keywords
seq
difficile
toxin
amino acid
mutant
Prior art date
Application number
RU2015154443A
Other languages
English (en)
Russian (ru)
Other versions
RU2015154443A3 (https=
RU2015154443A (ru
Inventor
Маниндер К. СИДХУ
Анналиеса Сибил АНДЕРСОН
Роберт Г.К. ДОНАЛД
Катрин Уте ЯНСЕН
Нарендер К. КАЛИАН
Терри Л. МИНИННИ
Джастин Кейт Моран
Марк Е. РУППЕН
Майкл Джеймс ФЛИНТ
Original Assignee
ВАЙЕТ ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ВАЙЕТ ЭлЭлСи filed Critical ВАЙЕТ ЭлЭлСи
Publication of RU2015154443A publication Critical patent/RU2015154443A/ru
Publication of RU2015154443A3 publication Critical patent/RU2015154443A3/ru
Application granted granted Critical
Publication of RU2754446C2 publication Critical patent/RU2754446C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2015154443A 2011-04-22 2012-04-20 Композиции, относящиеся к мутантному токсину CLOSTRIDIUM DIFFICILE, и способы их применения RU2754446C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161478474P 2011-04-22 2011-04-22
US61/478,474 2011-04-22
US201161478899P 2011-04-25 2011-04-25
US61/478,899 2011-04-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2013145170/10A Division RU2592686C2 (ru) 2011-04-22 2012-04-20 Композиции, относящиеся к мутантному токсину clostridium difficile, и способы их применения

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2017133138A Division RU2773880C1 (ru) 2011-04-22 2017-09-22 Композиции, относящиеся к мутантному токсину CLOSTRIDIUM DIFFICILE, и способы их применения

Publications (3)

Publication Number Publication Date
RU2015154443A RU2015154443A (ru) 2019-01-17
RU2015154443A3 RU2015154443A3 (https=) 2019-05-22
RU2754446C2 true RU2754446C2 (ru) 2021-09-02

Family

ID=46085103

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2015154443A RU2754446C2 (ru) 2011-04-22 2012-04-20 Композиции, относящиеся к мутантному токсину CLOSTRIDIUM DIFFICILE, и способы их применения
RU2013145170/10A RU2592686C2 (ru) 2011-04-22 2012-04-20 Композиции, относящиеся к мутантному токсину clostridium difficile, и способы их применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2013145170/10A RU2592686C2 (ru) 2011-04-22 2012-04-20 Композиции, относящиеся к мутантному токсину clostridium difficile, и способы их применения

Country Status (30)

Country Link
US (13) US8481692B2 (https=)
EP (4) EP3549949B1 (https=)
JP (8) JP5917682B2 (https=)
KR (1) KR101667837B1 (https=)
CN (3) CN103619871B (https=)
AR (1) AR086199A1 (https=)
AU (6) AU2012245904B2 (https=)
BR (2) BR122019017005B1 (https=)
CA (1) CA2832712C (https=)
CO (1) CO6801643A2 (https=)
DK (2) DK3549949T5 (https=)
ES (3) ES2742823T3 (https=)
FI (1) FI3549949T3 (https=)
HR (2) HRP20231631T1 (https=)
HU (2) HUE065594T2 (https=)
IL (8) IL270779B2 (https=)
MX (3) MX347521B (https=)
MY (2) MY182429A (https=)
NZ (1) NZ616035A (https=)
PE (2) PE20141029A1 (https=)
PH (1) PH12013502178B1 (https=)
PL (3) PL2699587T3 (https=)
PT (2) PT3549949T (https=)
RU (2) RU2754446C2 (https=)
SA (3) SA115360697B1 (https=)
SG (3) SG10201911993UA (https=)
SI (3) SI3549949T1 (https=)
TW (6) TWI815599B (https=)
WO (1) WO2012143902A1 (https=)
ZA (1) ZA201307818B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090311258A1 (en) * 2006-08-02 2009-12-17 Johannes Gutenberg-Universitaet Mainz Medicament for lct poisoning
SI2759306T1 (sl) * 2008-12-09 2016-05-31 Coley Pharmaceutical Group, Inc. Imunostimulacijski oligonukleotidi
PL2753352T5 (pl) 2010-09-03 2022-10-17 Valneva Austria Gmbh Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
TWI815599B (zh) 2011-04-22 2023-09-11 美商惠氏有限責任公司 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法
WO2013084071A2 (en) 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
ES2702315T3 (es) 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
US20140081659A1 (en) * 2012-09-17 2014-03-20 Depuy Orthopaedics, Inc. Systems and methods for surgical and interventional planning, support, post-operative follow-up, and functional recovery tracking
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN104780940B (zh) * 2012-11-06 2017-11-07 拜耳制药股份公司 用于双特异性t细胞衔接体(bites)的制剂
US9493518B2 (en) * 2013-03-14 2016-11-15 National Health Research Institutes Compositions and methods for treating clostridium difficile-associated diseases
WO2014144292A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
CN105451762A (zh) * 2013-04-22 2016-03-30 俄克拉荷马州大学评议会 艰难梭菌疫苗及使用方法
AU2014277981B2 (en) 2013-06-14 2019-06-20 Sanofi Pasteur Inc. Compositions and methods of immunizing against C. difficile
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
SG11201700089QA (en) * 2014-07-25 2017-02-27 Biosynth Srl Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria
WO2016130923A1 (en) * 2015-02-13 2016-08-18 Quanterix Corporation Immunoassays for diffrential detection of clostridium difficile
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
TWI767915B (zh) 2016-06-27 2022-06-21 加州大學董事會 Ror-1與btk拮抗劑的組合
US20190211377A1 (en) * 2016-12-22 2019-07-11 Roche Molecular Systems, Inc. Cobra probes to detect a marker for epidemic ribotypes of clostridium difficile
WO2019064115A1 (en) * 2017-09-28 2019-04-04 Pfizer Inc. COMPOSITIONS AND METHODS FOR GENERATING A DIFFICULT CLOSTRIDIUM IMMUNE RESPONSE
EP3946444A1 (en) * 2019-04-01 2022-02-09 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
WO2020231859A1 (en) * 2019-05-10 2020-11-19 The Board Of Regents Of The University Of Oklahoma Clostridioides difficile tcdb variants, vaccines and methods of use
WO2020231930A1 (en) * 2019-05-11 2020-11-19 The Texas A&M University System Protein inhibitors of clostridium difficile toxin b
KR102376876B1 (ko) 2020-04-09 2022-03-21 대진대학교 산학협력단 무독성의 클로스트리디움 디피실 독소단백질-단편 및 이의 용도
CN115697330A (zh) * 2020-05-06 2023-02-03 阿尔伯特·爱因斯坦医学院 通过抑制肠道损伤性细菌毒素TcdA和TcdB预防来自艰难梭菌感染的组织损伤的活性剂
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
CN111755068B (zh) * 2020-06-19 2021-02-19 深圳吉因加医学检验实验室 基于测序数据识别肿瘤纯度和绝对拷贝数的方法及装置
CN117580590A (zh) * 2021-07-02 2024-02-20 国立大学法人东京大学 用于抑制艰难梭菌的增殖的含有单克隆抗体的组合物
JP2025509460A (ja) 2022-03-14 2025-04-11 ファイザー・インク アジュバントを生産するための方法
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine
AU2023393199A1 (en) * 2022-12-13 2025-05-29 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
EP4658302A1 (en) 2023-02-02 2025-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition
WO2024196707A2 (en) * 2023-03-17 2024-09-26 The Board Of Trustees Of The University Of Illinois Chimeric antibody molecules based on tetrameric teleost immunoglobulin m
TWI909678B (zh) 2023-09-13 2025-12-21 美商輝瑞股份有限公司 產製佐劑之方法
WO2025257712A1 (en) 2024-06-12 2025-12-18 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010094970A1 (en) * 2009-02-20 2010-08-26 Health Protection Agency Antibodies to clostridium difficile toxins
RU2409385C2 (ru) * 2006-03-30 2011-01-20 Эмбрекс, Инк. Способ иммунизации птицы против инфекции, вызванной бактериями clostridium

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216123A (ja) 1982-06-10 1983-12-15 Kazue Ueno 抗血清
US4689299A (en) 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
US4713240A (en) 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5599539A (en) 1989-10-31 1997-02-04 Ophidian Pharmaceuticals, Inc. Therapy for clostridial botulinum toxin
US5578308A (en) 1990-02-12 1996-11-26 Capiau; Carine Glutaraldehyde and formalin detoxified bordetella toxin vaccine
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
WO1992018652A1 (en) 1991-04-22 1992-10-29 Massachusetts Health Research Institute, Inc. Process of screening plasma samples for effective antibody titers against respiratory viruses
US6221363B1 (en) 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
WO1994022476A1 (en) 1993-03-29 1994-10-13 Pfizer Inc. Multicomponent clostridial vaccines using saponin adjuvants
EP0779819A1 (en) 1994-09-06 1997-06-25 Galagen Inc. Therapeutic treatment of clostridium difficile associated diseases
NZ295998A (en) * 1994-10-24 1999-10-28 Ophidian Pharm Inc Neutralizing antitoxins against clostridium difficile and clostidium botulinum toxins
US6743430B1 (en) 1995-03-29 2004-06-01 Richard E. Parizek Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose
US5610023A (en) 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
NZ312502A (en) 1995-07-07 1999-03-29 Oravax Inc Clostridium difficile toxins as mucosal adjuvants
JPH11510793A (ja) 1995-07-07 1999-09-21 オラバックス インク． 胃腸病に対する鼻腔内ワクチン接種
ES2248822T3 (es) * 1995-09-15 2006-03-16 Dale N. Gerding Procedimientos y composiciones para la prevencion y el tratamiento de enfermedades asociadas al clostridium difficile.
IL127936A (en) 1996-07-12 2004-05-12 First Opinion Corp Computerized medical diagnostic system
ATE272409T1 (de) 1996-09-30 2004-08-15 Univ Arkansas Verfahren zur erzeugung aktiver immunität durch vakzinkonjugate
US20100267012A1 (en) 1997-11-04 2010-10-21 Bergeron Michel G Highly conserved genes and their use to generate probes and primers for detection of microorganisms
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US20050106157A1 (en) 1997-05-27 2005-05-19 Deckers Harm M. Immunogenic formulations comprising oil bodies
EP1000155A1 (en) 1997-06-20 2000-05-17 QUEEN MARY & WESTFIELD COLLEGE Immunogenic fragments of toxin a of clostridium difficile
DE19739685A1 (de) 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
EP1568378B1 (en) 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
EP2305303A3 (en) 1997-10-20 2013-11-13 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
JP2002542169A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン
JP2002541808A (ja) * 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
PT1187629E (pt) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
GB0008682D0 (en) 2000-04-07 2000-05-31 Microbiological Res Authority Transformation of clostridium difficile
EP1278764A4 (en) * 2000-05-04 2004-05-19 Harvard College CONNECTIONS AND METHODS FOR TREATING AND PREVENTING BACTERIAL INFECTIONS (11/14/01)
WO2003000719A2 (en) * 2001-06-20 2003-01-03 Ramot At Tel Aviv University Ltd. Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US7750204B2 (en) 2002-06-05 2010-07-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing antibody
WO2004041857A2 (en) * 2002-06-17 2004-05-21 Ballard Jimmy D Mutant of clostridium difficile toxin b and methods of use
US20040235139A1 (en) 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
RU2340627C2 (ru) * 2003-03-13 2008-12-10 ГлаксоСмитКлайн Байолоджикалз с.а. Способ очистки бактериального цитолизина
US20050020506A1 (en) 2003-07-25 2005-01-27 Drapeau Susan J. Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use
EP1709170B1 (en) 2004-01-16 2018-02-21 Pfenex Inc. Expression of mammalian proteins in pseudomonas fluorescens
NZ530709A (en) 2004-01-21 2006-07-28 Agres Ltd Improved IGA production method
DK2270045T3 (en) * 2004-02-06 2015-04-07 Univ Massachusetts ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINES AND APPLICATIONS THEREOF
GB0421083D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
WO2006071877A2 (en) * 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
WO2006130925A1 (en) 2005-06-10 2006-12-14 Monash University Genetic manipulation of clostridium difficile
GB0512751D0 (en) 2005-06-22 2005-07-27 Glaxo Group Ltd New adjuvant
EP1987361A4 (en) * 2006-01-30 2009-03-04 Invitrogen Corp COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING TOXIC SUBSTANCES IN DISEASE STATES
WO2007146139A2 (en) * 2006-06-08 2007-12-21 Cornell Research Foundation, Inc. Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b
GB0612301D0 (en) 2006-06-21 2006-08-02 Morvus Technology Ltd DNA molecules and methods
US20080206819A1 (en) 2006-08-21 2008-08-28 Mary Tsao Intensified Perfusion Production Method
US7775167B2 (en) 2006-08-22 2010-08-17 Monsanto Technology Llc Custom planter and method of custom planting
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
US9023352B2 (en) * 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
WO2008108082A1 (ja) * 2007-03-02 2008-09-12 Panasonic Corporation 音声復号装置および音声復号方法
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
US9096638B2 (en) 2007-09-06 2015-08-04 Geneohm Sciences Canada, Inc. Detection of toxigenic strains of Clostridium difficile
PL2198007T3 (pl) * 2007-09-14 2018-03-30 Sanofi Pasteur Biologics, Llc Kompozycje farmaceutyczne zawierające toksoidy A i B Clostridium difficile
WO2009132082A2 (en) * 2008-04-22 2009-10-29 Medical College Of Georgia Research Institute, Inc. Immunogenic compositions containing ceramide and methods of use thereof
US8206940B2 (en) 2008-05-15 2012-06-26 Tufts University Methods for diagnosis of Clostridium difficile and methods and vectors for recombinant toxin expression
EP2310045A1 (en) 2008-06-25 2011-04-20 Novartis AG Rapid responses to delayed booster immunisations
EP2146490A1 (en) 2008-07-18 2010-01-20 Alcatel, Lucent User device for gesture based exchange of information, methods for gesture based exchange of information between a plurality of user devices, and related devices and systems
CA2733425A1 (en) 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
EP2329029B1 (en) 2008-09-24 2016-06-08 Sanofi Pasteur Biologics, LLC Methods and compositions for increasing toxin production
US8444996B2 (en) 2008-10-01 2013-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia
WO2010037402A1 (en) * 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
UA105508C2 (uk) 2008-12-03 2014-05-26 Бьорінгер Інгельхайм Ветмедіка Гмбх Спосіб одержання вакцини проти clostridium difficile
SI2759306T1 (sl) 2008-12-09 2016-05-31 Coley Pharmaceutical Group, Inc. Imunostimulacijski oligonukleotidi
GB0901001D0 (en) * 2009-01-22 2009-03-04 Univ Nottingham Methods
WO2011031568A2 (en) * 2009-08-27 2011-03-17 Synaptic Research, Llc A NOVEL PROTEIN DELIVERY SYSTEM TO GENERATE INDUCED PLURIPOTENT STEM (iPS) CELLS OR TISSUE-SPECIFIC CELLS
US10046040B2 (en) * 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
WO2011068953A2 (en) 2009-12-02 2011-06-09 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
CN101870978A (zh) * 2010-03-23 2010-10-27 王世霞 密码子优化的艰难梭菌外毒素a羧基端基因序列及其核酸疫苗
KR20130072201A (ko) 2010-03-30 2013-07-01 피페넥스 인크. 재조합 독소 단백질의 고수준 발현
US8765399B2 (en) 2010-05-18 2014-07-01 Montefiore Medical Center Cultures and protocols for diagnosis of toxigenic Clostridium difficile
PL2753352T5 (pl) 2010-09-03 2022-10-17 Valneva Austria Gmbh Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania
GB201016742D0 (en) 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
EP2638063A4 (en) * 2010-11-12 2014-04-23 Reflexion Pharmaceuticals Inc GB1 PEPTIDE LIBRARIES AND CONNECTIONS AND SCREENING METHOD THEREFOR
TWI815599B (zh) * 2011-04-22 2023-09-11 美商惠氏有限責任公司 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法
HUE037126T2 (hu) 2011-05-27 2018-08-28 Glaxosmithkline Biologicals Sa Immunogén készítmény
US9770500B2 (en) * 2011-05-31 2017-09-26 The Board Of Regents Of The University Of Texas System S-nitrosylation of glucosylating toxins and uses therefor
WO2013084071A2 (en) 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
CA2882620A1 (en) 2012-09-19 2014-03-27 Novartis Ag Clostridium difficile polypeptides as vaccine
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN109776676A (zh) 2012-11-28 2019-05-21 Cnj控股公司 针对艰难梭菌的抗体
WO2014086787A1 (en) 2012-12-05 2014-06-12 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB201223342D0 (en) 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
WO2014144292A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
US20160045586A1 (en) 2013-03-15 2016-02-18 Sanofi Pasteur, Inc. Toxoid, Compositions and Related Methods
US20170165375A1 (en) 2013-04-02 2017-06-15 Stc. Unm Antibiotic protocells and related pharmaceutical formulations and methods of treatment
AU2014277981B2 (en) 2013-06-14 2019-06-20 Sanofi Pasteur Inc. Compositions and methods of immunizing against C. difficile
WO2015061529A1 (en) 2013-10-23 2015-04-30 The Rockefeller University Compositions and methods for prophylaxis and therapy of clostridium difficile infection
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3377613A1 (en) 2015-11-17 2018-09-26 Pfizer Inc Media and fermentation methods for producing polysaccharides in bacterial cell culture
MA44252A (fr) 2016-02-16 2018-12-26 Harvard College Vaccins contre des agents pathogènes et leurs procédés de production et d'utilisation
MX2019010948A (es) 2017-03-15 2020-01-09 Novavax Inc Métodos y composiciones para inducir respuestas inmunitarias contra clostridium difficile.
US10577665B2 (en) 2017-09-05 2020-03-03 Mcmaster University Aptamers for clostridium difficile detection
WO2019064115A1 (en) 2017-09-28 2019-04-04 Pfizer Inc. COMPOSITIONS AND METHODS FOR GENERATING A DIFFICULT CLOSTRIDIUM IMMUNE RESPONSE
JP6704173B2 (ja) 2019-09-26 2020-06-03 パナソニックＩｐマネジメント株式会社 開閉器及び分電盤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2409385C2 (ru) * 2006-03-30 2011-01-20 Эмбрекс, Инк. Способ иммунизации птицы против инфекции, вызванной бактериями clostridium
WO2010094970A1 (en) * 2009-02-20 2010-08-26 Health Protection Agency Antibodies to clostridium difficile toxins

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
EGERER M. et al., Autocatalytic Processing of Clostridium difficile Toxin B: BINDING OF INOSITOL HEXAKISPHOSPHATE, JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, v.284, n.6, p.3389 - 3395. *
EGERER M. et al., Autocatalytic Processing of Clostridium difficile Toxin B: BINDING OF INOSITOL HEXAKISPHOSPHATE, JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, v.284, n.6, p.3389 - 3395. TEICHERT M. et al., Application of Mutated Clostridium difficile Toxin A for Determination of Glucosyltransferase-Dependent Effects, INFECTION AND IMMUNITY, 2006, v.74, n.10, p.6006 - 6010. *
FRANKEL A.E. et al., Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor, Protein Eng, 2000, v.13, n.8, p.575-581. *
FRANKEL A.E. et al., Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor, Protein Eng, 2000, v.13, n.8, p.575-581. РОЙТ А. и др., "Иммунология", пер. с англ.- М.: Мир, 2000, 592 с. *
TEICHERT M. et al., Application of Mutated Clostridium difficile Toxin A for Determination of Glucosyltransferase-Dependent Effects, INFECTION AND IMMUNITY, 2006, v.74, n.10, p.6006 - 6010. *
РОЙТ А. и др., "Иммунология", пер. с англ.- М.: Мир, 2000, 592 с. *

Also Published As

Publication number Publication date
TWI815599B (zh) 2023-09-11
TWI701257B (zh) 2020-08-11
IL254418B (en) 2019-12-31
USRE48862E1 (en) 2021-12-28
IL254440A0 (en) 2017-11-30
IL270779B1 (en) 2024-05-01
CN107022532A (zh) 2017-08-08
CN107022532B (zh) 2021-05-04
IL273231B (en) 2021-08-31
MX391236B (es) 2025-03-21
HRP20240042T1 (hr) 2024-03-29
AU2019246878B2 (en) 2020-09-10
KR20130140206A (ko) 2013-12-23
DK3549949T3 (da) 2023-12-18
SA112330472B1 (ar) 2015-11-02
SA115360698B1 (ar) 2016-04-27
JP6892425B2 (ja) 2021-06-23
CA2832712A1 (en) 2012-10-26
EP4365196A2 (en) 2024-05-08
USRE46518E1 (en) 2017-08-22
IL254418A0 (en) 2017-11-30
RU2015154443A3 (https=) 2019-05-22
JP2021130692A (ja) 2021-09-09
SI2699587T1 (sl) 2019-08-30
TWI671313B (zh) 2019-09-11
JP2017125030A (ja) 2017-07-20
JP2018052938A (ja) 2018-04-05
SG10201602668VA (en) 2016-05-30
PH12013502178A1 (en) 2014-01-13
TWI804717B (zh) 2023-06-11
JP6097853B2 (ja) 2017-03-15
SA115360697B1 (ar) 2016-04-05
ES2968629T3 (es) 2024-05-13
BR122019017005B1 (pt) 2022-03-29
US8557548B2 (en) 2013-10-15
US9187536B1 (en) 2015-11-17
CN103619871A (zh) 2014-03-05
US20120269841A1 (en) 2012-10-25
EP3549949A1 (en) 2019-10-09
ZA201307818B (en) 2014-06-25
SG10201911993UA (en) 2020-02-27
DK3549949T5 (da) 2024-09-02
JP6321239B2 (ja) 2018-05-09
RU2013145170A (ru) 2015-06-27
KR101667837B1 (ko) 2016-10-20
CN111647059A (zh) 2020-09-11
JP7097478B2 (ja) 2022-07-07
EP3505531B1 (en) 2023-11-15
DK2699587T3 (da) 2019-08-05
USRE48863E1 (en) 2021-12-28
EP3549949B1 (en) 2023-11-29
EP2699587A1 (en) 2014-02-26
FI3549949T3 (fi) 2024-01-30
IL228944A (en) 2017-11-30
JP2016117745A (ja) 2016-06-30
AU2016202903A1 (en) 2016-05-26
TW201932480A (zh) 2019-08-16
AU2020230248A1 (en) 2020-10-01
PL2699587T3 (pl) 2019-12-31
AU2016202903B2 (en) 2017-11-30
AU2017261465A1 (en) 2017-11-30
PT2699587T (pt) 2019-09-05
US20130244307A1 (en) 2013-09-19
IL228944A0 (en) 2013-12-31
BR112013027229A2 (pt) 2016-11-29
JP2019052149A (ja) 2019-04-04
CO6801643A2 (es) 2013-11-29
AU2012245904B2 (en) 2016-04-21
TWI650329B (zh) 2019-02-11
JP2022126822A (ja) 2022-08-30
JP2018135345A (ja) 2018-08-30
US10597428B2 (en) 2020-03-24
US20150307563A1 (en) 2015-10-29
US20190202873A1 (en) 2019-07-04
AU2017261465B2 (en) 2018-10-04
PH12013502178B1 (en) 2018-11-09
ES2742823T3 (es) 2020-02-17
HRP20231631T1 (hr) 2024-03-15
WO2012143902A1 (en) 2012-10-26
TW202041525A (zh) 2020-11-16
NZ616035A (en) 2016-03-31
TW202320843A (zh) 2023-06-01
ES2969952T3 (es) 2024-05-23
EP3505531A1 (en) 2019-07-03
MX2013012344A (es) 2013-11-20
BR112013027229B1 (pt) 2020-10-27
MX347521B (es) 2017-04-27
USRE46376E1 (en) 2017-04-25
IL270779B2 (en) 2024-09-01
IL273231A (en) 2020-04-30
US20170313749A1 (en) 2017-11-02
HUE047085T2 (hu) 2020-04-28
EP2699587B1 (en) 2019-07-03
US10774117B2 (en) 2020-09-15
IL245047A0 (en) 2016-05-31
CA2832712C (en) 2018-08-28
US20130330371A1 (en) 2013-12-12
IL270779A (en) 2020-01-30
US20150125927A1 (en) 2015-05-07
IL254440B (en) 2019-12-31
MY182429A (en) 2021-01-25
SI3505531T1 (sl) 2024-02-29
SI3549949T1 (sl) 2024-02-29
TWI686402B (zh) 2020-03-01
IL265510B (en) 2021-05-31
US9745354B2 (en) 2017-08-29
JP5917682B2 (ja) 2016-05-18
AU2018201296A1 (en) 2018-03-15
JP6735784B2 (ja) 2020-08-05
IL265510A (en) 2019-05-30
MY168205A (en) 2018-10-15
AU2020230248B2 (en) 2022-12-01
AR086199A1 (es) 2013-11-27
PL3505531T3 (pl) 2024-03-11
MX385834B (es) 2025-03-18
AU2019246878A1 (en) 2019-10-31
US20230391835A1 (en) 2023-12-07
CN111647059B (zh) 2023-11-28
RU2015154443A (ru) 2019-01-17
AU2012245904A1 (en) 2013-10-17
EP4365196A3 (en) 2024-08-07
PE20181334A1 (es) 2018-08-21
RU2592686C2 (ru) 2016-07-27
US20200095290A1 (en) 2020-03-26
HUE065594T2 (hu) 2024-06-28
TW201806967A (zh) 2018-03-01
PT3549949T (pt) 2024-02-02
IL255345B (en) 2021-05-31
US11535652B2 (en) 2022-12-27
CN103619871B (zh) 2016-12-14
TW201932481A (zh) 2019-08-16
JP2014514318A (ja) 2014-06-19
PL3549949T3 (pl) 2024-04-08
SG194132A1 (en) 2013-11-29
US8900597B2 (en) 2014-12-02
IL255345A0 (en) 2017-12-31
US8481692B2 (en) 2013-07-09
PE20141029A1 (es) 2014-09-04
TW201302780A (zh) 2013-01-16

Similar Documents

Publication Publication Date Title
RU2754446C2 (ru) Композиции, относящиеся к мутантному токсину CLOSTRIDIUM DIFFICILE, и способы их применения
AU2019203159B2 (en) Compositions and methods relating to a mutant clostridium difficile toxin
KR102532707B1 (ko) 대장균 o-항원 다당류의 바이오컨쥬게이트, 이의 제조 방법, 및 이의 사용 방법
KR102625114B1 (ko) 클로스트리디움 디피실레에 대항한 면역 반응을 도출하기 위한 조성물 및 방법
KR20140117433A (ko) 재조합 독소를 포함하는, 클로스트리디움 디피실레에 대한 백신
KR102574882B1 (ko) 대장균 o-항원 다당류의 바이오컨쥬게이트의 생성 방법, 이의 조성물 및 이의 사용 방법
KR20140101835A (ko) 클로스트리듐 디피실레 톡신-기반 백신
KR20230043157A (ko) 다가 백신 조성물 및 이의 용도
KR20150056540A (ko) 백신으로서의 클로스트리듐 디피실 폴리펩티드
RU2773880C1 (ru) Композиции, относящиеся к мутантному токсину CLOSTRIDIUM DIFFICILE, и способы их применения
RU2773917C2 (ru) Композиции и способы для вызывания иммунного ответа против clostridium difficile
AU2021240230B2 (en) Vaccines and vaccine components for inhibition of microbial cells